Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5515229 | 0.87 | KDM4E (0.37) | KDM4EALDH1A1DPP4GAALMNA | |
| SCHEMBL6093550 | 0.86 | HTT (0.40) | ALDH1A1POLBKMT2ALMNA | |
| SCHEMBL5524869 | 0.83 | KDM4E (0.39) | KDM4EALDH1A1POLBHSD17B10DPP4 | |
| SCHEMBL7530712 | 0.81 | KDM4E (0.38) | KDM4EALDH1A1DPP4GAALMNA | |
| SCHEMBL5512857 | 0.81 | KDM4E (0.38) | KDM4EALDH1A1HSD17B10DPP4KMT2A | |
| SCHEMBL5512817 | 0.78 | KDM4E (0.42) | KDM4EALDH1A1HSD17B10DPP4GAA | |
| SCHEMBL8133519 | 0.78 | HTT (0.41) | KDM4EALDH1A1POLBKMT2AGAA | |
| SCHEMBL5509867 | 0.77 | KDM4E (0.40) | KDM4EALDH1A1HSD17B10DPP4GAA | |
| SCHEMBL4708030 | 0.76 | KDM4E (0.37) | KDM4EALDH1A1HSD17B10DPP4KMT2A | |
| SCHEMBL5508711 | 0.76 | KDM4E (0.38) | KDM4EALDH1A1POLBHSD17B10DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238812-B2 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | MEJI SEIKA KAISHA, LTD. (JP) | 2007-07-03 | — | — | US | disclosed |
| US-20060074074-A1 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2006-04-06 | — | — | US | disclosed |
| US-7022860-B2 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1026167-B1 | TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND ANTIALLERGIC AGENTS | MEIJI SEIKA KAISHA (JP) | 2003-03-05 | — | — | EP | disclosed |
| US-20020137739-A1 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2002-09-26 | — | — | US | disclosed |
| US-6372735-B1 | ANTIHISTAMINES | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074074-A1 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | HRH4, CYP2D6, CYP2B6 | KDM4E 752/4885ALDH1A1 959/4885POLB 2970/4885 |
| US-20020137739-A1 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | HRH4, CYP3A4, TPH1 | KDM4E 547/4885ALDH1A1 691/4885POLB 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.